Loading
NASDAQHealthcareBiotechnology
Latest quote
$28.5467
+$0.8167 · +2.95%
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Regular session
$28.5467
+$0.8167 · +2.95%
Regular session · ET · Market data may be delayed.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Day range
Current $28.5467
52-week range
Current $28.5467
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
31
Expensive
Sentiment
64
Bullish
Risk
40
Moderate Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Day range
Current $28.5467
52-week range
Current $28.5467
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 431K USD | — | — | — | — |
| Gross profit | −431K USD | — | — | — | — |
| Research and development | 344.96M USD | 101.64M USD | 63.81M USD | 54.23M USD | 44.98M USD |
| Selling, general, and administrative | 48.39M USD | 49.28M USD | 37.02M USD | 16.12M USD | 10.7M USD |
| Operating expenses | 393.34M USD | 150.92M USD | 100.83M USD | 70.36M USD | 55.68M USD |
| Interest income | 33.7M USD | 40.94M USD | 15.02M USD | 1.59M USD | 703K USD |
| Interest expense | — | 94K USD | 88K USD | 59K USD | 18K USD |
| Depreciation and amortization | 431K USD | 346K USD | 292K USD | 291K USD | 296K USD |
| Operating income | −393.34M USD | −150.92M USD | −100.83M USD | −70.36M USD | −55.68M USD |
| Net income | −359.64M USD | −109.96M USD | −85.9M USD | −68.87M USD | −54.99M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$97.80
242.60% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI115.05M0.00%2.3T USD0.03%$382.08+0.66%
State Street SPDR S&P Biotech ETFXBI99.1M0.98%10.11B USD0.35%$153.87+3.07%
Vanguard Morningstar Small-Cap ETFVB83.14M0.04%185.3B USD0.03%$289.68+0.71%
Vanguard Morningstar Small-Cap Growth ETFVBK47.85M0.10%44.7B USD0.05%$345.1+1.32%
Vanguard Extended Market ETFVXF44.28M0.05%95.4B USD0.05%$235.14+0.86%
Schwab U.S. Small-Cap ETFSCHA18.76M0.09%21.73B USD0.03%$32.825+0.51%
iShares Russell Mid-Cap ETFIWR13.95M0.02%55.97B USD0.18%$109.84+0.89%
Vanguard Health Care ETFVHT11.02M0.05%22B USD0.09%$319.35+1.75%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Russell Mid-Cap ETFIWRVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
